Associated Papers
Tumor DNA from tumor in situ fluid was used to track evolution of glioma under first-line treatment.
Yu J et al.
Frontiers in Oncology, 2025
41179686 (PubMed )
Supplement: Table3.xls › Continuous_TISF_monitoring
Increased KRAS G12C Prevalence, High Tumor Mutational Burden, and Specific Mutational Signatures Are Associated With MUTYH Mutations: A Pan-Cancer Analysis.
Disel U et al.
The Oncologist, 2024
37589222 (PubMed )
Supplement: oyad230_suppl_supplementary_tables.xlsx › Supplementary_Table_2
In Silico Analysis of nsSNPs of Human KRAS Gene and Protein Modeling Using Bioinformatic Tools.
Xu D et al.
Acs Omega, 2023
Predicting the effects of rare genetic variants on oncogenic signaling pathways: A computational analysis of HRAS protein function.
Ali S et al.
Frontiers in Chemistry, 2023
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
35244186 (PubMed )
Supplement: Supplementary_Data2.xlsx › Feuil1
The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence.
Rabbie R et al.
British Journal of Cancer, 2021
Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.
Trédan O et al.
Targeted Oncology, 2013
Select a paper to view details